Moderna's stock surged 176.9% to $174.38 on August 19, 2026, boosting its market cap to about $69.6 billion. The company expects to end 2026 with $4.7-$5.2 billion in cash and investments, plus a $0.9 billion credit line. CEO Stéphane Bancel highlighted Moderna's transition into a growth phase but has not indicated any immediate merger or acquisition plans. Potential acquisition targets include Immatics, Arbutus Biopharma, Intellia Therapeutics, and Editas Medicine, all players in mRNA and genetic medicine. The sector is consolidating, with recent deals by BioNTech, Eli Lilly, and Vertex, positioning Moderna as a strong bidder with increased financial power, though management emphasizes cautious spending.
Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive l...
Tempus AI agreed to acquire Personalis for $1.5 billion in a stock deal, gaining access to Personalis's ultrasensitive cancer DNA detection test, NeXT Personal. This technology supports a personalized mRNA cancer vaccine by Moderna and Merck, which r...
Moderna's stock surged over 125% in one week, driven by positive interim results from its Phase 3 trial of a personalized mRNA cancer vaccine for high-risk melanoma patients. The trial, conducted with partner Merck, showed success without new safety ...
Moderna's stock jumped 93% following the announcement that its Phase 3 melanoma trial, conducted with Merck, met its primary endpoint by significantly improving recurrence-free survival when combined with Merck's Keytruda. This marks the first positi...
Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phas...
